Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma
| Autor: | Osman Öcal, Maciej Pech, Peter Malfertheiner, Max Seidensticker, Jens Ricke, Christian Sengel, Bora Peynircioglu, Otto M. van Delden, Muzaffer Reha Ümütlü, Irene Bargellini, Bernhard Gebauer, Michael Ingrisch, Alberto Benito, Roberto Iezzi, Christian Loewe, Christoph J. Zech, Vincent Vandecaveye |
|---|---|
| Přispěvatelé: | CCA -Cancer Center Amsterdam, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, ACS - Amsterdam Cardiovascular Sciences, Radiology and Nuclear Medicine, CCA - Imaging and biomarkers |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Sorafenib
Male Cancer Research medicine.medical_specialty Carcinoma Hepatocellular Pleural effusion Hepatocellular carcinoma Antineoplastic Agents Article Prognostic markers Post-hoc analysis Ascites Biomarkers Tumor Medicine Humans Aged medicine.diagnostic_test business.industry Selective internal radiation therapy Liver Neoplasms Magnetic resonance imaging Bilirubin medicine.disease Prognosis Magnetic Resonance Imaging Tumor Burden Oncology Liver Female Radiology Liver function medicine.symptom business medicine.drug |
| Zdroj: | British Journal of Cancer British journal of cancer, 126(2), 211-218. Nature Publishing Group |
| ISSN: | 0007-0920 |
| Popis: | Summary Aims To investigate the prognostic value of baseline imaging features for overall survival (OS) and liver decompensation (LD) in patients with hepatocellular carcinoma (HCC). Design Patients with advanced HCC from the SORAMIC trial were evaluated in this post hoc analysis. Several radiological imaging features were collected from baseline computed tomography (CT) and magnetic resonance imaging (MRI) imaging, besides clinical values. The prognostic value of these features for OS and LD (grade 2 bilirubin increase) was quantified with univariate Cox proportional hazard models and multivariate Least Absolute Shrinkage and Selection Operator (LASSO) regression. Results Three hundred and seventy-six patients were included in this study. The treatment arm was not correlated with OS. LASSO showed satellite lesions, atypical HCC, peritumoral arterial enhancement, larger tumour size, higher albumin–bilirubin (ALBI) score, liver–spleen ratio Conclusions Imaging features showing aggressive tumour biology and poor liver function, in addition to clinical parameters, can serve as imaging biomarkers for OS and LD in patients receiving sorafenib and selective internal radiation therapy for HCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink